FDA | Building Blocks

Warning!
Your browser does not support JavaScript or JavaScript support is disabled.
Display of the content may be incorrect. Please make sure that JavaScript is enabled in your browser. Warning!
Apparently you are using proxy server to access this site.
It means that display of the content may be incorrect.

Warning!
Your browser does not support HTML5.
Display of the content may be incorrect. Please make sure that your browser supports HTML5 syntax.

Home News Building Block Analogs of Capmatinib

3 August 2020

Building Block Analogs of Capmatinib

Capmatinib (TABRECTA) approved by FDA in May 2020 for the treatment of non-small cell lung cancer. Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with antineoplastic activity. It selectively binds to c-Met, inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. Capmatinib contains 2-fluoro-N-methylbenzamide moiety in its backbone.

We have made a set of in-stock Building Blocks, which contain such part – the perfect start for your research!

Building Block Analogs of Capmatinib

Enquire for x () from in

Enquire for

Would you like to submit a custom request?

Enquiry for a list of compounds

Please select the ship to country:

Sign in